ZeptoMetrix competitors

Key experiences in leading mergers and acquisitions, working with financial institutions and markets, driving exceptional growth in revenue and profit, developing organizations, managing organizational performance, and planning strategic growth. Specialties: Mergers and acquisitions, General Management, Marketing, Sales, Quality Systems.

Richard Maradie is a Chief Executive Officer at NOVAVAX INC and is based in Rockville, Maryland.

John Simard is a Chairman/President/CEO/Founder at XBiotech USA Inc, VP/Founder at MANNKIND CORP, and Board Member at MANNKIND CORP. He attended University of Toronto.

Highly motivated senior executive with general management experience in both large multi-national companies and small private equity environments in the diagnostic, medical device, pharmaceutical and life science industries. Demonstrated performance excellence in multi-disciplinary leadership roles including operations, marketing, sales, strategic planning, acquisitions and integrations on domestic and international level. Excel at turning around underperforming businesses with a combination of strong business acumen, outstanding leadership, customer relationships, and superior commercial execution. Dynamic leader with ability to build high performing teams and cross functional collaboration, align and inspire organizations towards a clear vision, and execute for sustainable results.

Adam Simpson is the chief executive officer (CEO) of Icosavax. He has substantial life science operational and emerging company experience and has executed significant partnering and acquisition transactions. Previously, Adam was CEO of PvP Biologics, another spinout from University of Washington’s Institute for Protein Design (IPD), from company creation through its sale to Takeda. Prior to joining PvP Biologics, he was the president and chief operating officer of Cypher Genomics, a genome interpretation company focused on biomarker discovery to facilitate drug development, through its sale to Human Longevity, Inc. Prior to that, Adam was a cofounder and chief business officer of Meritage Pharma, a company developing treatments for upper gastrointestinal disorders, from company creation through its staged sale to Shire, and at Verus Pharmaceuticals, a company focused on treatments for asthma and anaphylaxis, where as general counsel he led its sale to AstraZeneca and Shionogi. He has been a cofounder of four additional life sciences companies that have either gone public or been acquired. Adam started his career as an attorney at Latham & Watkins. He holds a B.S. in biochemistry from the University of California, San Diego, and received his J.D. from the University of Minnesota Law School.